NOVOPHARM RANITIDINE FORM 1 CONTAINS DETECTABLE AMOUNTS FORM 2, GLAXO CONTENDS AT TRIAL; CLAIMS NOVOPHARM STOLE MANUFACTURING TRADE SECRETS
Novopharm's generic version of Glaxo Wellcome's Zantac contains detectable amounts of Form 2 ranitidine hydrochloride, Glaxo contended in opening statements April 16 in Elizabeth City, N.C. federal court in a suit Glaxo filed against Novopharm for its filing of an ANDA for Form 1 ranitidine.
You may also be interested in...
Sanofi-Synthelabo's latest patent for its antithrombotic Plavix covers the polymorphic form of clopidogrel that is currently marketed in the U.S., the company said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011